Chinese biotech firm Arctic Vision moves to create an integrated ophthalmology powerhouse by acquiring MDCO Technology's device business, combining drug and device expertise to address unmet needs in eye care.
While investors chase AI and big tech, a niche biotech firm focused on rare genetic obesity disorders has quietly delivered staggering returns, with Wall Street seeing further 40% upside. Rhythm Pharmaceuticals' targeted approach and upcoming catalysts have analysts bullish, despite its relative anonymity.
With a cash reserve that could last just over a year at its current burn rate, InflaRx faces a critical period to prove its clinical pipeline's value. While management has reined in spending, the company's financial strategy is now under the microscope.
While EyePoint Pharmaceuticals (EYPT) shares have retreated 23% this month, long-term shareholders are still sitting on massive gains. The biotech's 195% three-year surge, despite ongoing losses, highlights a classic market puzzle: balancing current financials with future potential.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility dedicated to next-generation weight-loss drugs, signaling a long-term strategic commitment to the obesity market amid intense competition.
Immunocore Holdings (IMCR) shares have experienced notable turbulence, declining over 7% in a week. Yet, a significant gap between its current price and analyst fair value estimates highlights a debate over the biotech's future, heavily reliant on its lead asset KIMMTRAK and pipeline execution.
The vital Rafah border crossing between Gaza and Egypt has partially reopened after a prolonged closure, a key provision of the US-mediated ceasefire. The move allows for limited humanitarian movement under stringent security oversight by Israel and Egypt.
ABIVAX (NASDAQ:ABVX) shares have skyrocketed over 2000% in recent months, fueled by speculation of an Eli Lilly buyout and promising clinical data for its lead drug. CEO Marc De Garidel has publicly dismissed the acquisition rumors as 'noise,' redirecting focus to the company's financing needs and advancing therapeutic programs.
Takeda Pharmaceutical raises its FY2025 revenue and profit guidance following resilient nine-month results and announces U.S. availability of a new ready-to-use immunoglobulin therapy for primary immunodeficiency, fueling discussions on its growth strategy amid high debt and margin pressures.
Boston Scientific's latest earnings beat and raised guidance, fueled by strong demand for its electrophysiology devices, signal a strategic shift. The company is navigating tariff pressures while expanding margins, with major acquisitions poised to reshape its long-term profile.
Glaukos Corporation secures a significant FDA nod allowing repeated administration of its sustained-release iDose TR implant, broadening treatment options for patients with glaucoma and potentially reshaping long-term care paradigms.
Travere Therapeutics faces a securities fraud investigation by Robbins Geller Rudman & Dowd LLP, raising questions about the accuracy of its past disclosures. The probe casts a shadow over the company's critical transition, as it banks on its kidney drug FILSPARI to drive growth amid mounting legal and commercial pressures.
Shares of Tyson Foods (TSN) have climbed over 12% in the past month, reigniting discussions on Wall Street about the meatpacking giant's valuation. While some analysts see room for further growth, others caution that recent gains may have outpaced fundamentals.
The Israeli government has ordered Médecins Sans Frontières (MSF) to cease operations in Gaza by the end of February, citing the aid group's refusal to hand over details of its Palestinian staff—a move critics decry as a dangerous politicization of humanitarian aid.
Marsh McLennan Agency unveils a group captive insurance solution designed specifically for senior living communities, aiming to provide stable liability coverage and risk management support in a challenging market.
As Merck prepares to release its fourth-quarter results, investors are watching to see if the pharmaceutical leader can maintain its track record of exceeding expectations amid a slowing growth outlook.
In an exclusive interview, Robert F. Kennedy Jr. addresses the state of his relationship with cousin Caroline Kennedy following the death of her daughter, Tatiana Schlossberg, last December. The tragedy unfolds against a backdrop of deep political rifts within America's most storied political dynasty.
Health and Human Services Secretary Robert F. Kennedy Jr. has publicly addressed the deep divisions within America's most storied political family, following the death of his cousin Tatiana Schlossberg and amidst ongoing policy controversies that have placed him at odds with his relatives.
As China's pork industry grapples with overcapacity and falling prices, a growing appetite for premium, flavorful black pork among the middle class is offering a lifeline to farmers and reshaping market strategies.
A reported fiery exchange between JPMorgan's Jamie Dimon and Coinbase's Brian Armstrong at the World Economic Forum lays bare the intensifying battle between traditional finance and the crypto industry over regulation, deposits, and the future of money.
